Silence Therapeutics (SLN) Non-Current Assets (2018 - 2026)
Silence Therapeutics (SLN) posted Non-Current Assets of $12.3 million for Q1 2026, down 4.01% sequentially from $12.8 million in Q4 2025, and down 20.87% YoY from $15.5 million in Q1 2025.
Silence Therapeutics (SLN) Non-Current Assets (2018 - 2026) Analysis & Trends
Silence Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $12.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 20.87% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (down 20.87% YoY) and the FY2025 annual result came in at $12.8 million, down 16.27% from the prior year.
- Non-Current Assets eased to $12.3 million in Q1 2026 per SLN's latest filing, from $12.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $16.7 million in Q2 2025 and troughed at -$113.4 million in Q4 2022.
- A 5-year average of -$16.0 million and a median of $13.0 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets soared 115.18% in 2024, then fell 20.87% in 2026.
- Over 5 years, Non-Current Assets stood at -$113.4 million in 2022, then increased by 11.33% to -$100.6 million in 2023, then jumped by 115.18% to $15.3 million in 2024, then dropped by 16.27% to $12.8 million in 2025, then fell by 4.01% to $12.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $12.3 million, $12.8 million, and $13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.13 Mn |
| Mar 31, 2026 | 12.27 Mn |
| Dec 31, 2025 | 12.78 Mn |
| Sep 30, 2025 | 13.16 Mn |
| Jun 30, 2025 | 16.68 Mn |
| Mar 31, 2025 | 15.51 Mn |
| Dec 31, 2024 | 15.27 Mn |
| Dec 31, 2023 | -100.56 Mn |
| Dec 31, 2022 | -113.41 Mn |
| Dec 31, 2021 | -116.38 Mn |
| Dec 31, 2020 | -100.88 Mn |
| Dec 31, 2019 | -48.17 Mn |
| Dec 31, 2018 | -37.96 Mn |